We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.59B
1-Year Est. Return 234.06%
This Fund
S&P 500
This Quarter Est. Return
+23.3%
1 Year Est. Return
+234.06%
3 Year Est. Return
+822.97%
5 Year Est. Return
+865.41%
10 Year Est. Return
+12,585.11%
AUM
$1.61B
AUM Growth
+$111M
Cap. Flow
-$113M
Cap. Flow %
-6.99%
Top 10 Hldgs %
70.44%
Holding
46
New
2
Increased
1
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$17.8M
2
RGLS
Regulus Therapeutics
RGLS
+$7.37M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$1.08M

Top Sells

Rank Stock Value
1
MYND
Mynd.ai
MYND
+$98.8M
2
GERN icon
Geron
GERN
+$22.4M
3
SGMT icon
Sagimet Biosciences
SGMT
+$13.3M
4
CBIO
Crescent Biopharma
CBIO
+$2.78M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$1.29M

Sector Composition

Rank Sector Weight
1 Healthcare 86.79%
2 Consumer Staples 6.72%
3 Technology 3.98%
4 Industrials 2.07%
5 Communication Services 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DM
26
DELISTED
Desktop Metal, Inc.
DM
$12.7M 0.79%
1,440,759
– –
CBIO
27
Crescent Biopharma
CBIO
$698M
$11.5M 0.71%
38,350
-9,294
-20% -$2.78M
SGMT icon
28
Sagimet Biosciences
SGMT
$650M
$10.8M 0.67%
2,000,275
-1,850,000
-48% -$13.3M
TUYA
29
Tuya Inc
TUYA
$1.09B
$8.64M 0.54%
4,934,640
– –
CSBR icon
30
Champions Oncology
CSBR
$66.4M
$8.4M 0.52%
1,713,720
– –
OKUR
31
OnKure Therapeutics
OKUR
$119M
$7.94M 0.49%
478,549
– –
ALLK
32
DELISTED
Allakos
ALLK
$7.75M 0.48%
6,147,260
– –
BZFD icon
33
BuzzFeed
BZFD
$87.5M
$7.16M 0.44%
3,833,473
– –
LXRX icon
34
Lexicon Pharmaceuticals
LXRX
$894M
$5.72M 0.35%
2,382,286
– –
IVA
35
Inventiva
IVA
$912M
$5.29M 0.33%
1,462,586
– –
SYBX
36
DELISTED
Synlogic
SYBX
$5.23M 0.32%
2,922,772
-2
-0% -$5
MRKR icon
37
Marker Therapeutics
MRKR
$19.5M
$4.61M 0.29%
1,071,428
– –
AFMD
38
DELISTED
Affimed
AFMD
$2.35M 0.15%
442,649
– –
SNTI icon
39
Senti Biosciences Holdings
SNTI
$9.34M
$1.67M 0.1%
442,615
– –
MYND
40
Mynd.ai
MYND
$17.6M
$1.57M 0.1%
3,642,711
-20,000,000
-85% -$98.8M
XERS icon
41
Xeris Biopharma Holdings
XERS
$1.37B
$926K 0.06%
+419,100
New +$1.08M
IMA
42
ImageneBio Inc
IMA
$55.8M
$809K 0.05%
47,504
– –
UP icon
43
Wheels Up
UP
$119M
$305K 0.02%
5,306
– –
SRFM icon
44
Surf Air Mobility
SRFM
$57.9M
$186K 0.01%
31,458
– –
ACRV icon
45
Acrivon Therapeutics
ACRV
$78.4M
– –
-430,252
Closed -$1.29M
ADXN
46
Addex Therapeutics
ADXN
$4.13M
– –
-9,000
Closed -$306K
1
2

Similar funds

ADL
Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return
CCP
Cryder Capital Partners London, United Kingdom $1.59B AUM 0.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
W
Wealthquest Cincinnati, Ohio $1.59B AUM 18.1% 1-Year Est. Return
PIS
PPSC Investment Service Tokyo, Japan $1.58B AUM 47.89% 1-Year Est. Return
FWP
Falcon Wealth Planning Ontario, California $1.58B AUM 20.99% 1-Year Est. Return

NEA Management Company's Q1 2024 Portfolio in Review

As of Q1 2024, NEA Management Company held 46 positions worth $1.61B, up 7.4% from $1.5B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

NEA Management Company withdrew a net $113M in Q1 2024, closing 2 positions and reducing 5 holdings. Its most notable exit was Acrivon Therapeutics, an estimated $1.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 78% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, NEA Management Company opened a new position in Oric Pharmaceuticals worth $20.6M.

  • NEA Management Company's largest Q1 2024 buy was Oric Pharmaceuticals: 1,500,000 shares worth $20.6M.
  • NEA Management Company added most to Regulus Therapeutics in Q1 2024, an estimated $7.37M increase.
  • NEA Management Company's biggest Q1 2024 reduction was Mynd.ai, cutting an estimated $98.8M.
  • NEA Management Company fully exited Acrivon Therapeutics in Q1 2024, selling an estimated $1.29M.
  • NEA Management Company's ten largest holdings make up 70% of its $1.61B portfolio in Q1 2024.
  • NEA Management Company opened 2 new positions and closed 2 in Q1 2024.
  • NEA Management Company's portfolio value rose 7.4% quarter-over-quarter to $1.61B.

Based on NEA Management Company's 13F filing for Q1 2024, filed 15 May 2024.